AstraZeneca Surrenders India Licence For Olaparib Tablets

AstraZeneca Pharma on Tuesday said it has surrendered the marketing authorisation for Olaparib (Lynparza) tablets in 100 mg and 150 mg strengths due to commercial reasons.

The company had received approval for the product in November 2023 but had not marketed it in India. In an exchange filing, AstraZeneca clarified that the decision was not related to efficacy or safety concerns and that it continues to hold other existing approvals for Olaparib in the country.

Olaparib is used in combination with Abiraterone and Prednisone or Prednisolone for the treatment of prostate cancer in adult patients.